OBJECTIVE: To correlate quality of life (QoL) and physical limitations in histological proven primary brain tumor patients using a battery of generic, disease-specific and symptom questionnaires. METHODS: Thirty patients with primary brain tumors were selected from a neuro-oncology outpatient clinic. The FACT-Br Functional Assessment of Cancer Therapy-Brain (specific quality of life questionnaire for patients with brain tumors), SF-36 (generic quality of life questionnaire), HADS (anxiety and depression), and Barthel Index (functionality scale) were answered by the patients at the same interview. RESULTS: The Barthel index did not demonstrate correlation with any subscale of the FACT-Br questionnaire. The HADS had a negative correlation with all FACT-Br subscales and its total score. The SF-36 had a significant weak to moderate correlation with the FACT-Br questionnaire. CONCLUSION: Considering that the FACT-Br is a quick specific questionnaire, it can be a valuable and simple option in evaluating QoL in brain tumor patients with good functional capacity.
OBJECTIVE: To correlate quality of life (QoL) and physical limitations in histological proven primary brain tumorpatients using a battery of generic, disease-specific and symptom questionnaires. METHODS: Thirty patients with primary brain tumors were selected from a neuro-oncology outpatient clinic. The FACT-Br Functional Assessment of Cancer Therapy-Brain (specific quality of life questionnaire for patients with brain tumors), SF-36 (generic quality of life questionnaire), HADS (anxiety and depression), and Barthel Index (functionality scale) were answered by the patients at the same interview. RESULTS: The Barthel index did not demonstrate correlation with any subscale of the FACT-Br questionnaire. The HADS had a negative correlation with all FACT-Br subscales and its total score. The SF-36 had a significant weak to moderate correlation with the FACT-Br questionnaire. CONCLUSION: Considering that the FACT-Br is a quick specific questionnaire, it can be a valuable and simple option in evaluating QoL in brain tumorpatients with good functional capacity.
Authors: A Bezjak; J Adam; R Barton; T Panzarella; N Laperriere; C S Wong; W Mason; C Buckley; W Levin; M McLean; J S Y Wu; M Sia; P Kirkbride Journal: Eur J Cancer Date: 2002-03 Impact factor: 9.162
Authors: N Scott Litofsky; Elana Farace; Frederick Anderson; Christina A Meyers; Wei Huang; Edward R Laws Journal: Neurosurgery Date: 2004-02 Impact factor: 4.654
Authors: Ronald Chow; Nicholas Lao; Marko Popovic; Edward Chow; David Cella; Jennifer Beaumont; Henry Lam; Natalie Pulenzas; Gillian Bedard; Erin Wong; Carlo DeAngelis; Andrew Bottomley Journal: Support Care Cancer Date: 2014-09 Impact factor: 3.603
Authors: Quirien Oort; Hanneke Zwinkels; Johan A F Koekkoek; Maaike J Vos; Jaap C Reijneveld; Martin J B Taphoorn; Linda Dirven Journal: Psychooncology Date: 2022-01-28 Impact factor: 3.955
Authors: Michelle J Naughton; L Douglas Case; Ann Peiffer; Michael Chan; Volker Stieber; Dennis Moore; Steven Falchuk; James Piephoff; William Edenfield; Jeffrey Giguere; Monica Loghin; Edward G Shaw; Stephen R Rapp Journal: Neurooncol Pract Date: 2017-07-06